Efzofitimod: A Novel Therapeutic Candidate for SSc-ILD D. Siefker, Z. Xu, C. Burkart, M. Ferrer, C. Polizzi, K. Rauch, S. Klopp-Savino, L. Guy, E. Yu, L. Glendening, Y. Qing, Y. Chong, R. Adams, L. Nangle













Disclosures:

All authors are employees of aTyr Pharma, Inc. Funding support: This work was supported by aTyr Pharma, Inc.

References:

²Stifano G, et. al. Chronic Toll-like receptor 4 stimulation in skin induces inflammation, macrophage activation, transforming growth factor beta signature gene expression, and fibrosis. Arthritis Research and Therapy. 16:R136 (2014) ³Stifano G, et. al. Skin gene expression is prognostic for the trajectory of skin disease in patients with diffuse cutaneous systemic sclerosis. Arthritis Rheumatol. 70,1 (2018) ⁴Culver D, et. al. Efzofitimod for the Treatment of Pulmonary Sarcoidosis. *Chest.* 163 (4) (2023)

aTyr Pharma - San Diego (USA)

¹Baughman, RP, et al. Efzofitimod: A novel anti-inflammatory agent for sarcoidosis. Sarcoidosis, Vasculitis and Diffuse Lung Diseases. 40,1 (2023)